These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 27895023)

  • 21. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ; Benes LB; Lee L; Dayspring TD; Sorrentino M; Davidson M
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):54-61. PubMed ID: 29940784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV; Cokkinos P; Kolovou G
    Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract]   [Full Text] [Related]  

  • 24. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
    Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM
    Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
    Banach M; Penson PE
    Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
    [No Abstract]   [Full Text] [Related]  

  • 28. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Access to PCSK9 Inhibitors.
    Baum SJ; Lepor NE; Robinson JG
    Rev Cardiovasc Med; 2018; 19(S1):S47-S50. PubMed ID: 30207557
    [No Abstract]   [Full Text] [Related]  

  • 31. PCSK9 inhibitor valuation: A science-based review of the two recent models.
    Baum SJ; Cannon CP
    Clin Cardiol; 2018 Apr; 41(4):544-550. PubMed ID: 29512936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of cardiovascular risk with evolocumab (Repatha).
    Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071
    [No Abstract]   [Full Text] [Related]  

  • 34. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors.
    Cicero AFG; Toth PP; Fogacci F; Virdis A; Borghi C
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):527-529. PubMed ID: 30954414
    [No Abstract]   [Full Text] [Related]  

  • 38. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B; Tselmin S; Bornstein SR; Julius U
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.